


# 2026 ACCP Annual Meeting

“Harnessing Changing Clinical Pharmacology Paradigms  
to Improve Patient Outcomes”

September 27 – 29, 2026 • N Bethesda, Maryland



## 2026 ACCP Distinguished Investigator Award

### R. Scott Obach, PhD

Vice President, Scientific Research  
Pfizer Global Research & Development

Dr. Scott Obach is head of the ADME Sciences Biotransformation Group in PDM at Pfizer. For 33 years his role in Pfizer’s early research has been to aid in the design of new drugs that will have good exposure in the body, and his role in the later phase of drug development has been to characterize how the body metabolizes and excretes individual drug candidates in support of registration dossiers. Products he has worked on have included Chantix®, Geodon®, Zoloft® and Paxlovid®, among others. His research interests include application of *in vitro* approaches to study drug metabolism, mechanisms of drug metabolism reactions, and prediction of human pharmacokinetics and drug interactions from *in vitro* data.

Dr. Obach earned his PhD in biochemistry in 1990 from Brandeis Univ and conducted postdoctoral research on cytochrome P450 enzymes at the New York State Dept of Health Research Laboratories. He is an author or co-author on over 240 research publications, is an associate editor of *Drug Metabolism and Disposition*, and served a term as President of the Int’l Society for the Study of Xenobiotics (ISSX). He is a fellow of the Japanese Society for the Study of Xenobiotics (JSSX) and has won three awards for Scientific Achievement from ISSX (North America in 2012, International in 2025 and Drug Discovery in 2024).